Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer

Purpose The purpose of this study was to identify the concordant or discordant genomic profiling between primary and matched metastatic tumors in patients with colorectal cancer (CRC) and to explore the clinical implication. Materials and Methods Surgical samples of primary and matched metastatic tissues from 158 patients (335 samples) with CRC at Korea University Anam Hospital were evaluated using the Ion AmpliSeq Cancer Hotspot Panel. We compared genetic variants and classified them as concordant, primary-specific, and metastasis-specific variants. We used a combination of principal components analysis and clustering to find genomic groups. Kaplan-Meier curves were used to appraise survival between genomic groups. We used machine learning to confirm the correlation between genetic variants and metastatic sites. Results A total of 282 types of deleterious non-synonymous variants were selected for analysis. Of a total of 897 variants, an average of 40% was discordant. Three genomic groups were yielded based on the genomic discrepancy patterns. Overall survival differed significantly between the genomic groups. The poorest group had the highest proportion of concordant KRAS G12V and additional metastasis-specific SMAD4. Correlation analysis between genetic variants and metastatic sites suggested that concordant KRAS mutations would have more disseminated metastases. Conclusion Driver gene mutations were mostly concordant; however, discordant or metastasis-specific mutations were present. Clinically, the concordant driver genetic changes with additional metastasis-specific variants can predict poor prognosis for patients with CRC.

[1]  G. Poston,et al.  Prognostic and predictive markers in liver limited stage IV colorectal cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  B. Taylor,et al.  Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer , 2019, Clinical Cancer Research.

[3]  W. Klepetko,et al.  Mutational profile of colorectal cancer lung metastases and paired primary tumors by targeted next generation sequencing: implications on clinical outcome after surgery. , 2018, Journal of thoracic disease.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  V. Donckier,et al.  The concept of oligometastases in colorectal cancer: from the clinical evidences to new therapeutic strategies , 2018, Current opinion in oncology.

[6]  K. White,et al.  Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis , 2018, Nature Communications.

[7]  L. Xia,et al.  Tumor-Associated Macrophages Derived TGF-β‒Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4/Snail Signaling Pathway , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[8]  M. Lai,et al.  Mutations of key driver genes in colorectal cancer progression and metastasis , 2018, Cancer and Metastasis Reviews.

[9]  Z. Pan,et al.  Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis , 2017, Journal of Cancer Research and Clinical Oncology.

[10]  Woo Yong Lee,et al.  Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer , 2017, Clinical Cancer Research.

[11]  R. Mountford,et al.  Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer , 2017, British Journal of Cancer.

[12]  R. Kamps,et al.  Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification , 2017, International journal of molecular sciences.

[13]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[14]  Trevor A Graham,et al.  New paradigms in clonal evolution: punctuated equilibrium in cancer , 2016, The Journal of pathology.

[15]  P. Majno,et al.  Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases , 2015, The British journal of surgery.

[16]  T. de Baère,et al.  Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[18]  E. Steyerberg,et al.  Racial variations in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing , 2015, Genetics in Medicine.

[19]  V. Zellmer,et al.  Evolving concepts of tumor heterogeneity , 2014, Cell & Bioscience.

[20]  Vladimir Vacic,et al.  Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions , 2014, Genome Biology.

[21]  F. Eggerding,et al.  Identification of an APC Variant in a Patient with Clinical Attenuated Familial Adenomatous Polyposis , 2014, Case reports in medicine.

[22]  J. Valcárcel,et al.  Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.

[23]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[24]  Min P. Kim,et al.  Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. , 2012, The Annals of thoracic surgery.

[25]  K. Hemminki,et al.  Colorectal cancer patients: what do they die of? , 2012, Frontline Gastroenterology.

[26]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[27]  Pierre Laurent-Puig,et al.  Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.

[28]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[29]  Andrew Dunford,et al.  Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.

[30]  R. Weichselbaum,et al.  Oligometastases revisited , 2011, Nature Reviews Clinical Oncology.